HK Stock Market Move | ALPHAMAB-B(09966) rises more than 7%. Previously announced plans to repurchase shares on the exchange. Market attention on key data from the ESMO conference.

ALPHAMAB-B (09966) rose more than 7%, as of press time, it increased by 6.79% to HK$14.63, with a turnover of HK$37.113 million. On the news front, Kangning Jerui Pharmaceuticals announced that on October 16, the company spent HK$5.483 million to repurchase 400,000 shares. The company had previously announced that, in accordance with the general authorization granted to the directors (share repurchase authorization approved by shareholders at the annual general meeting of shareholders held on June 12, 2025), the Board of Directors resolved on October 12, 2025 to repurchase the Company's ordinary shares (shares) from time to time from the open market, with the maximum amount of the repurchase being HK$20 million. In addition, the European Society for Medical Oncology (ESMO) in 2025 will be held in Berlin, Germany from October 17 to 21, where the latest research abstracts will be presented. It is reported that 23 studies from China have been selected for presentation, including key studies such as Kangning Jerui KN026.